Adjuvant Avelumab in Merkel Cell Cancer

Summary

This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2017-12-19

Primary completion

2029-01-31

Completion

2029-02-18

Drugs

Indications

No indication recorded.